| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 84.41 | 6.3% |
| Total Income | 85.06 | 5.8% |
| Expenditure | 73.67 | 5.2% |
| PBT | 11.39 | 9.3% |
| Net Profit | 8.52 | 0.8% |
| OPM | 4.72% | 0.84pp |
| NPM | 10.02% | 0.65pp |
| EPS | 8.21 | 0.7% |
Kwality Pharmaceuticals Reports 8% Increase in Q3FY25 Revenue, Secures 10 New Product Approvals
01 Feb 2025 · 1 Feb 2025, 12:44 am
Summary
Kwality Pharmaceuticals Ltd ('KPL') reported an 8% increase in consolidated revenue to Rs 85.06 crores in Q3FY25 compared to Rs 78.71 crores in the same quarter previous year. EBITDA grew 5% to Rs 18.2 crores compared to Rs 17.3 crores in the same quarter previous year. The company received SFDA (Saudi Arabia) approval for both general and beta injectables, enabling it to expand its product offerings in GCC and Middle East regions. KPL secured 10 new product approvals for marketing oncology products, further strengthening its position in this therapeutic area. The company started supplying Leuprorelin acetate 11.25mg in Greece, marking a significant milestone in its international expansion in the Europe markets. KPL initiated preclinical trials for its first-ever biosimilar Erythropoietin. The company aims to double revenues by FY26 from FY23 levels with sustainable EBITDA margins ranging from 22-25%.
Key Highlights
- 1
8% increase in consolidated revenue to Rs 85.06 crores in Q3FY25
- 2
5% growth in EBITDA to Rs 18.2 crores in Q3FY25
- 3
Received SFDA (Saudi Arabia) approval for general and beta injectables
- 4
Secured 10 new product approvals for marketing oncology products
- 5
Initiated preclinical trials for KPL's first-ever biosimilar Erythropoietin
- 6
Started supplying Leuprorelin acetate 11.25mg in Greece
Management Comments
Managing Director
KPL received SFDA (Saudi Arabia) approval for both general and beta injectables, enabling us to expand our product offerings in GCC and Middle East regions. In addition, KPL has secured 10 new product approvals for marketing oncology products, further strengthening our position in this therapeutic area. KPL has also started supplying Leuprorelin acetate 11.25mg in Greece, marking a significant milestone in our international expansion in the Europe markets. Leuprorelin acetate 11.25mg is used in the treatment of prostate cancer to help control the growth of cancer cells. Furthermore, we have initiated preclinical trials for KPL's first-ever biosimilar Erythropoietin, a major achievement for the company, following the approval from the RCGM. These accomplishments will help in expanding our portfolio and global reach. We remain focussed to double revenues by FY26 from FY23 levels with sustainable EBITDA margins ranging from 22-25%.
Informational and educational content only. Not investment advice.